Cargando…
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
Programmed death-ligand 1 (PD-L1) expression is a predictor of immune checkpoint inhibitor (ICI) treatment efficacy. The clinical efficacy of ICIs for non-small-cell lung cancer (NSCLC) patients harboring major mutations, such as EGFR or ALK mutations, is limited. We genotyped 190 patients with adva...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178012/ https://www.ncbi.nlm.nih.gov/pubmed/32283823 http://dx.doi.org/10.3390/ijms21072623 |
_version_ | 1783525356695715840 |
---|---|
author | Oya, Yuko Kuroda, Hiroaki Nakada, Takeo Takahashi, Yusuke Sakakura, Noriaki Hida, Toyoaki |
author_facet | Oya, Yuko Kuroda, Hiroaki Nakada, Takeo Takahashi, Yusuke Sakakura, Noriaki Hida, Toyoaki |
author_sort | Oya, Yuko |
collection | PubMed |
description | Programmed death-ligand 1 (PD-L1) expression is a predictor of immune checkpoint inhibitor (ICI) treatment efficacy. The clinical efficacy of ICIs for non-small-cell lung cancer (NSCLC) patients harboring major mutations, such as EGFR or ALK mutations, is limited. We genotyped 190 patients with advanced lung adenocarcinomas who received nivolumab or pembrolizumab monotherapy, and examined the efficacy in NSCLC patients with or without major mutations. Among the patients enrolled in the genotyping study, 47 patients harbored EGFR mutations, 25 patients had KRAS mutations, 5 patients had a HER2 mutation, 6 patients had a BRAF mutation, and 7 patients had ALK rearrangement. The status of PD-L1 expression was evaluated in 151 patients, and the rate of high PD-L1 expression (≥50%) was significantly higher in patients with ALK mutations. The progression-free survival was 0.6 (95% CI: 0.2–2.1) months for ALK-positive patients and 1.8 (95% CI: 1.2–2.1) months for EGFR-positive patients. All patients with ALK rearrangement showed disease progression within three months from the initiation of anti-PD-1 treatment. Our data suggested that ICI treatment was significantly less efficacious in patients with ALK rearrangement than in patients with EGFR mutations, and PD-L1 expression was not a critical biomarker for ICI treatment for patients with one of these mutations. |
format | Online Article Text |
id | pubmed-7178012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71780122020-04-28 Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement Oya, Yuko Kuroda, Hiroaki Nakada, Takeo Takahashi, Yusuke Sakakura, Noriaki Hida, Toyoaki Int J Mol Sci Article Programmed death-ligand 1 (PD-L1) expression is a predictor of immune checkpoint inhibitor (ICI) treatment efficacy. The clinical efficacy of ICIs for non-small-cell lung cancer (NSCLC) patients harboring major mutations, such as EGFR or ALK mutations, is limited. We genotyped 190 patients with advanced lung adenocarcinomas who received nivolumab or pembrolizumab monotherapy, and examined the efficacy in NSCLC patients with or without major mutations. Among the patients enrolled in the genotyping study, 47 patients harbored EGFR mutations, 25 patients had KRAS mutations, 5 patients had a HER2 mutation, 6 patients had a BRAF mutation, and 7 patients had ALK rearrangement. The status of PD-L1 expression was evaluated in 151 patients, and the rate of high PD-L1 expression (≥50%) was significantly higher in patients with ALK mutations. The progression-free survival was 0.6 (95% CI: 0.2–2.1) months for ALK-positive patients and 1.8 (95% CI: 1.2–2.1) months for EGFR-positive patients. All patients with ALK rearrangement showed disease progression within three months from the initiation of anti-PD-1 treatment. Our data suggested that ICI treatment was significantly less efficacious in patients with ALK rearrangement than in patients with EGFR mutations, and PD-L1 expression was not a critical biomarker for ICI treatment for patients with one of these mutations. MDPI 2020-04-09 /pmc/articles/PMC7178012/ /pubmed/32283823 http://dx.doi.org/10.3390/ijms21072623 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Oya, Yuko Kuroda, Hiroaki Nakada, Takeo Takahashi, Yusuke Sakakura, Noriaki Hida, Toyoaki Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement |
title | Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement |
title_full | Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement |
title_fullStr | Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement |
title_full_unstemmed | Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement |
title_short | Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement |
title_sort | efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer with alk rearrangement |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178012/ https://www.ncbi.nlm.nih.gov/pubmed/32283823 http://dx.doi.org/10.3390/ijms21072623 |
work_keys_str_mv | AT oyayuko efficacyofimmunecheckpointinhibitormonotherapyforadvancednonsmallcelllungcancerwithalkrearrangement AT kurodahiroaki efficacyofimmunecheckpointinhibitormonotherapyforadvancednonsmallcelllungcancerwithalkrearrangement AT nakadatakeo efficacyofimmunecheckpointinhibitormonotherapyforadvancednonsmallcelllungcancerwithalkrearrangement AT takahashiyusuke efficacyofimmunecheckpointinhibitormonotherapyforadvancednonsmallcelllungcancerwithalkrearrangement AT sakakuranoriaki efficacyofimmunecheckpointinhibitormonotherapyforadvancednonsmallcelllungcancerwithalkrearrangement AT hidatoyoaki efficacyofimmunecheckpointinhibitormonotherapyforadvancednonsmallcelllungcancerwithalkrearrangement |